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Abstract
Introduction: Functional alterations of the cystic fibrosis transmembrane
conductance regulator gene (CFTR) increase the viscoelasticity of pulmonary
secretions of cystic fibrosis (CF) patients and require the use of therapeutic
aerosols. The biochemical properties of exocrine secretions are influenced by
the expression of the FUT2 gene which determine the secretor and non-secretor
phenotypes of the ABH glycoconjugates. The aim of this study was to determine
the influence of secretor and non-secretor phenotypes by means of
photoacoustic analysis, both the typical interaction time (t0) and the
solubilization interval (Δt) of the sputum of secretor and non-secretor CF patients
nebulized by hypertonic saline solutions at different concentrations.
Material and methods: Sputum samples were obtained by spontaneous
expectoration from 6 secretor and 4 non-secretor patients with CF. Each sample
was nebulized with 3%, 6%, and 7% hypertonic saline solutions in
a photoacoustic cell. The values of t0 and Δt were determined using the Origin
7.5® computer program (Microcal Software Inc.). The t-test was employed using
the GraphPad Instat 3.0® computer program to calculate the mean and standard
deviation for each parameter.
Results: For all hypertonic saline solutions tested, the mean values of t0 and Δt
do not show statistically significant differences between secretor and non-
secretor patients.
Conclusions: The secretor and non-secretor phenotypes do not influence the in
vitro solubilization of the sputum nebulized by hypertonic saline solutions at
different concentrations when analysed by photoacoustic technique.
Key words: photoacoustic technique, secretor phenotype, cystic fibrosis, hypertonic
saline solutions.
Introduction
Cystic fibrosis (CF) is an autosomal recessive disease resulting from
cystic fibrosis transmembrane conductance factor (CFTR) gene alterations
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affecting the CFTR protein function contributing to
increased viscoelasticity of pulmonary secretions,
which represents the main risk factor for the
development of irreversible pulmonary disease [1].
Additionally, dehydration of the pulmonary
secretions, bacterial infections and infiltration of
neutrophils also contribute to an increase in the
viscoelasticity of the pulmonary mucus [2]. As
a consequence, CF patients have difficulty to
eliminate pulmonary secretions and are required
to use therapeutic aerosols to solubilize them and
facilitate expectoration [3].
The secretor and non-secretor phenotypes are
genetic traits related to the ABO histo-blood group
system under control of the FUT2 gene (19q13.3).
Carriers of secretor phenotype produce ABH
glycoconjugates (glycoproteins and glycolipids) in
the exocrine secretions according to their ABO blood
types. On the other hand, carriers of non-secretor
phenotype are unable to secrete these glyco  -
conjugates [4]. Therefore, the presence or absence
of ABH glycoconjugates alters the biochemical
properties of exocrine secretions as they reflect the
nature of part of the carbohydrates in secretions
[5, 6]. 
Previous papers failed to demonstrate an
association between CF, the ABO histo-blood group
system, and secretor and non-secretor phenotypes
based on statistical analysis, although a protective
effect of the secretor phenotype on epithelialized
organs has been proposed [7-10]. 
The photoacoustic technique is useful to
evaluate the interaction between therapeutic
aerosols and exocrine secretions. It allows the
determination of the typical interaction time (t0)
between the aerosol and the secretion sample and
the solubilization interval (Δt) in minutes. The
photoacoustic effect consists in the production of
acoustic waves due to the absorption of modulated
light by the secretion sample. Light energy absorbed
is converted into heat, modulating the temperature
which produces the mechanical effect of periodic
expansion and contraction, originating sound waves
that can be detected by a microphone. The
photoacoustic signal depends on the optical and
thermal properties of the sample, which may vary
with time. When a sample undergoes changes in
its biochemical composition or structure, the
propagation of heat produced inside is modified
thereby altering the photoacoustic signal [11].
Our recent demonstration that the secretor and
non-secretor phenotypes influence the solu  -
bilization of pulmonary mucus from CF patients 
by nebulization with tobramycin and α dornase
using the photoacoustic technique [12] prompted
us to investigate whether other therapeutic
aerosols used by CF patients can be influenced by
those genetic traits under control of the FUT2 gene.
The aim of this study was to determine the
influence of secretor and non-secretor phenotypes
by means of photoacoustic analysis, both the
typical interaction time (t0) and the solubilization
interval (Δt) of the sputum of secretor and non-
secretor CF patients nebulized by hypertonic saline
solutions at different concentrations.
Material and methods
Ethical considerations
This study was approved by the Research Ethics
Committee of the FAMERP (case 366/2006). Written
informed consent was obtained after the parents
and/or guardians of the patients were informed
about the protocol study. 
Patient selection
To perform this in vitro experimental study, ten
Caucasians CF patients, 5 men and 5 women, 
with mean age 16.9 years old (range: 10 years old
to 29 years old), able to expectorate spontaneously,
were selected. Six of them are regularly treated in
the Cystic Fibrosis Reference Center of the Medical
School in Sa ~o José do Rio Preto (FUNFARME) and
four in the Cystic Fibrosis Reference Center of the
State University in Campinas (UNICAMP). Seven
patients had the ΔF508 mutation and one had the
G542X mutation in the CFTR gene. Two patients had
not had the disease confirmed by molecular
analysis but all of them had CF diagnosis confirmed
by the positive sweat test and also by measuring
the faecal fat, which are the gold standard.
Although a small number of patients was
selected, it was sufficient to demonstrate the
difference for the secretor and non-secretor
phenotypes influencing both the typical interaction
time (t0) and the solubilization interval (Δt) as
reported in our previous paper [12].
Blood sampling and extraction of genomic DNA
A sample of 5 ml of whole blood was drawn from
each patient and placed in vacuum tubes with
EDTA. White blood cells were used for the extraction
of genomic DNA according to the protocol of Miller
et al. [13].
Secretor and non-secretor phenotype
identification
The secretor and non-secretor phenotypes were
identified by FUT2 genotyping using PCR-RFLP
according to the protocol of Svensson et al. [14].
Briefly, a fragment containing 1033 base pairs from
exon 2 of the FUT2 gene with primers sense 
(5’-CGC TCC TTC AGC TGG GCA CTG GA-3’) and
antisense (5’-CGG CCT CTC AGG TGA ACC AAG AAG328 Arch Med Sci 2, April / 2011
CT-3’) to differentiate the G and A alleles at the 428
position was amplified. Each PCR mix was
performed in a final volume of 25 μl containing
10 mM TRIS-HCl, 50 mM KCl, 1.5 mM MgCl2, 20 mM
of each dNTP (dATP, dTTP, dCTP, dGTP), 10 pM of
each primer, 0.5 U of Taq and 5 ng of genomic DNA.
The amplification conditions involved pre-
denaturation (94°C for 5 min) followed by 35 cycles
(94°C for 1 min, 63°C for 1 min and 72°C for 1 min)
and an additional extension at 72°C for 5 min. The
amplified fragments were digested by Ava II enzyme
given a variable number of fragments (459, 295, 149
and 130 base pairs for the G allele; 459, 425 and
149 base pairs for the A allele) which were
separated by electrophoresis in 2% agarose gel
stained with ethidium bromide under UV light.
Thus, GG and GA individuals were identified as
secretors and AA individuals as non-secretors of
ABH glycoconjugates.
Sputum sample collection
By spontaneous expectoration, 5 ml of pulmo  -
nary mucus were collected onto a universal collector
and covered with sterile gauze to absorb any excess
saliva, according to the protocol of Bossi [15].
Subsequently, it was placed in polystyrene tubes
lubricated with liquid Vaseline to avoid dehydration
and stored at –20°C until photoacoustic analysis.
Routine laboratory tests were performed to rule out
the presence of pulmonary infection.
Preparation of 3%, 6% and 7% hypertonic
saline solutions
The hypertonic saline solutions at 3%, 6% and
7% were prepared by diluting a 20% NaCl stock
solution using distilled water and following the
formula below:
V1 × C1 = V2 × C2
where V1 indicates the volume of 20% NaCl
solution to be diluted, C1 the concentration of 20%,
V2 the final volume to be obtained and C2 the final
desired concentration.
Preparation of the sputum samples for
photoacoustic analysis
The samples were naturally thawed at room
temperature and subsequently submersed in xylol
for 5 s to remove the liquid Vaseline. Each sample
was divided into three portions with volumes 
of 0.1 ml for a double blind fashion photoacoustic
analysis.
Determination of t0 and Δt by photoacoustic
analysis
The protocol used to perform the photoacoustic
analyses was based on our previous study [11]. Each
sputum sample was evaluated for a period of 5 min
to measure the baseline photoacoustic signal
before applying each hypertonic saline solution to
assess the stability of the photoacoustic signal.
Increases or decreases of this signal over time
would compromise later analysis of the
solubilization process. Next, each sputum sample
was individually nebulized with each hypertonic
saline solution concentration and its solubilization
was evaluated by monitoring the amplitude of the
photoacoustic signal over time. The evolution over
time of the photoacoustic signal was adjusted using
the Boltzmann equation given by:
A1 – A2 PA(t) =   + A2
1 + e
t – t0
Δt
where PA(t) is the amplitude of the photo  -
acoustic signal at time t, A1 and A2 are the baseline
and final amplitudes of the photoacoustic signal,
respectively, t0 is the maximum solubilization and
Δt the effective time interval corresponding to the
solubilization process. Figure 1 shows the standard
curve for the adjustment of the photoacoustic
signal of the t0 and Δt parameters. The data were
transferred to a computer and adjustment curves
were produced by the Origin 7.5® computer program
(Microcal Software Inc.). The t-test, using the
GraphPad Instat 3.0® computer program, calculated
the mean and standard deviation for each
adjustment parameter.
Results
According the results of FUT2 genotyping, the
patients were classified as secretor (60%; 6/10) and
non-secretor (40%; 4/10) phenotypes.
The mean values of t0 and Δt for each of the
hypertonic saline solution concentrations tested are
shown in Table I. Although the solubilization of the
pulmonary mucus from secretors nebulized with
3% presents a higher value for t0 as compared with
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Figure 1. Standard curve for the adjustment of the
photoacoustic signal (PA) for the typical interaction
time (t0) and solubilization interval (Δt) parameters
P
A
 
s
i
g
n
a
lArch Med Sci 2, April / 2011 329
CF sputum solubility by HSS 
non-secretors, the difference was not statistically
significant. Similar mean values for t0 and Δt were
observed for solubilization with hypertonic saline
solution at 6% and 7% for both secretor and non-
secretor phenotype carriers as well.
Discussion
Our study was aimed at determining, by using
the photoacoustic technique, the influence of the
secretor and non-secretor phenotypes in the
solubilization of the pulmonary sputum from cystic
fibrosis patients treated regularly with hypertonic
saline solutions. The typical interaction time of
solubilization (t0) and the solubilization interval (Δt)
were measured after the nebulization of the
sputum by hypertonic saline solutions at 3%, 6%
and 7%. 
The utility of the photoacoustic technique to
evaluate the interaction of human mucous with
therapeutic aerosols has been proved [11, 12]. The
results reported by Dumas et al. supported the
empirical practice of the use of isotonic saline
solutions to clear the airways of healthy individuals
and patients presenting pulmonary symptoms as
well [11]. However, this study did not investigate the
influence of the secretor and non-secretor
phenotypes on the solubilization of the sputum.
Our recent previous study demonstrating the
influence of secretor and non-secretor phenotypes
on the solubilization of the CF sputum nebulized in
vitro by tobramycin and α dornase shed some light
on the importance of genetic traits and drug
interactions [12]. Therefore this approach could be
used to validate the utility of phenotyping and
genotyping before the prescription of drugs
including therapeutic aerosols used by CF patients.
The results of this investigation are in disagreement
with those reported in our previous study [12] since
the differences of t0 and Δt for secretor and non-
secretor phenotype carriers were not statistically
significant for all the hypertonic saline solutions
tested. The homogeneity of the results may be due
to various factors.
Unlike tobramycin and dornase α, hypertonic
saline solutions are not conventional medicines but
also contribute to the solubilization of secretions
[16-19]. Due to differences in osmolarity these
hypertonic solutions act as hydrating secretions by
removing water from the epithelial cells that line
the airways [17, 18]. Moreover, they exert
a mucolytic effect by breaking the ionic links
between the glycoproteins of the mucus, thereby
considerably reducing the viscoelasticity of the
pulmonary secretions and facilitating the
expectorations [16, 19].
Biochemical properties of the exocrine
secretions are influenced, at least in part, by the
presence of the ABH glycoconjugates. These
glycosylated molecules related to the ABO blood
group system are expressed under control of the
FUT2  gene and reflect the nature of the
carbohydrates present in exocrine secretions [5, 6].
Secretors differ from non-secretor carriers as they
express glycoproteins and glycolipids with distinct
ABH antigenic specificities. The oligosaccharidic
structures of these glyco  conju  gates are constituted
of glucose, N-acetylglucos  amine, fucose, galactose
and N-acetylgalactosamine [4]. The control of
glycosylation, responsible for the creation of ABH
glycoconjugates, is performed by the α-2-L-
fucosyltransferase enzyme coded by the FUT2
gene, which determines the dynamics of
glycosylation of the proteins and lipids in exocrine
secretions, including in pulmonary mucus [20, 21].
Majima et al. reported that the high level of
fucose present in nasal mucus correlates with an
increase in its viscoelasticity [22]. This monosac  -
charide, present in purified respiratory mucus
glycoproteins produced by goblet cells and
submucosal gland cells and ABH glycoconjugates
as well, largely contributes to the viscoelasticity of
the nasal mucus in chronic sinusitis [23]. However,
the solubilization of the sputum nebulized by
hypertonic saline solutions seems not to be
dependent on fucose. 
The presence of the FUT2 gene, apart from
defining the secretor phenotype, contributes to
a reduction in the length of the oligosaccharide
chains of ABH glycoconjugates [5, 24]. On the other
hand, the substitution of G428A in exon 2 of this
gene, apart from abolishing the α-2-L-fucosyltrans  -
ferase enzyme expression, determines the non-
secretor phenotype, the absence of ABH glycocon  -
jugates and the presence of long precursor
oligo  saccharide chains [24, 25]. These structural
differences may cause variation in the polarity and
the hydrosolubility of the sputum from secretor and
Positive  Negative  Value of p
secretor (n = 6) secretor (n = 4)
3% NaCl 
t0 14.3 ±4.7 9.6 ±5.8 0.23
Δt 3.0 ±1.3 3.0 ±2.5 0.99
6% NaCl 
t0 13.8 ±7.3 13.8 ±4.0 0.98
Δt 2.7 ±1.7 2.9 ±2.5 0.89
7% NaCl 
t0 11.6 ±3.8 11.2 ±1.0 0.83
Δt 3.7 ±3.0 3.0 ±2.8 0.70
Table I. Mean values in minutes and respective
standard deviations of t0 and Δt using different
concentrations of hypertonic saline solution in
sputum of positive and negative secretors330 Arch Med Sci 2, April / 2011
non-secretors but they could not be enough to
influence the solubilization of the sputum when
nebulized by hypertonic saline solutions. 
The differences resulting from the presence or
absence of the ABH glycoconjugates in exocrine
secretions play an important biological role in the
innate immunity of different microorganisms,
including those that infect the airways causing
pulmonary damage [6, 10]. However, the solu  -
bilization of sputum of secretor and non-secretor
CF patients by hypertonic saline solutions is
apparently independent of differences determined
by the FUT2 gene.
Since monogenetic traits have a predictable
influence on therapeutic response to a large
number of commonly prescribed medicines [26], it
would be expected that secretor and non-secretor
phenotypes could be useful to determine the
adequate time for CF patients to spend in therapy,
as we suggested in our previous paper [12].
However, the homogeneity of the data for t0 and
Δt seems to indicate that the secretor and non-
secretor phenotypes have no effect on the
solubilization of sputum from CF patients when
nebulized by hypertonic saline solutions. 
In conclusion, the secretor and non-secretor
phenotypes do not influence the in vitro solu  -
bilization of the sputum nebulized by hypertonic
saline solutions at different concen  trations when
analysed by photoacoustic measur  ements.
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